DDDD 4d Pharma Plc

TIDMDDDD

4d Pharma PLC

29 June 2021

THIS IS A REACH ANNOUNCEMENT AND THE INFORMATION CONTAINED IS NOT CONSIDERED TO BE MATERIAL OR TO HAVE A SIGNIFICANT IMPACT ON MANAGEMENT'S EXPECTATIONS OF THE COMPANY'S PERFORMANCE. REACH IS AN INVESTOR COMMUNICATION SERVICE AIMED AT ASSISTING LISTED AND UNLISTED (INCLUDING AIM QUOTED) COMPANIES TO DISTRIBUTE NON-REGULATORY NEWS RELEASES INTO THE PUBLIC DOMAIN. INFORMATION REQUIRED TO BE NOTIFIED UNDER THE AIM RULES FOR COMPANIES, MARKET ABUSE REGULATION OR OTHER REGULATION WOULD BE DISSEMINATED AS AN RNS REGULATORY ANNOUNCEMENT AND NOT ON REACH.

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

Leeds, UK, June 29, 2021 - 4D pharma plc (AIM: DDDD, NASDAQ, LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET (7:30pm BST).

A webcast of the presentation will be available via the 'Events' section of the 4D pharma website at www.4dpharmaplc.com . An archived replay of the webcast will be available for 90 days following the presentation.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R) in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

Contact Information:

4D pharma

Investor Relations: ir@4dpharmaplc.com

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASEAFLAEFSELM

(END) Dow Jones Newswires

June 29, 2021 02:00 ET (06:00 GMT)

4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024

4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024